KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVS) Other Accumulated Expenses (2017 - 2023)

Novartis Ag's Other Accumulated Expenses history spans 7 years, with the latest figure at $516.0 million for Q4 2023.

  • For Q4 2023, Other Accumulated Expenses fell 38.28% year-over-year to $516.0 million; the TTM value through Dec 2023 reached $516.0 million, down 38.28%, while the annual FY2023 figure was $516.0 million, 38.28% down from the prior year.
  • Other Accumulated Expenses for Q4 2023 was $516.0 million at Novartis Ag, down from $836.0 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $836.0 million in Q4 2022 and bottomed at $471.0 million in Q4 2019.
  • The 5-year median for Other Accumulated Expenses is $619.0 million (2021), against an average of $638.2 million.
  • The largest annual shift saw Other Accumulated Expenses soared 59.02% in 2020 before it crashed 38.28% in 2023.
  • A 5-year view of Other Accumulated Expenses shows it stood at $471.0 million in 2019, then soared by 59.02% to $749.0 million in 2020, then decreased by 17.36% to $619.0 million in 2021, then skyrocketed by 35.06% to $836.0 million in 2022, then plummeted by 38.28% to $516.0 million in 2023.
  • Per Business Quant, the three most recent readings for NVS's Other Accumulated Expenses are $516.0 million (Q4 2023), $836.0 million (Q4 2022), and $619.0 million (Q4 2021).